Navigation Links
Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
Date:5/1/2008

25,322 23,227 9.0%

NET INCOME 51,980 49,109 5.8%

Net income per common share

assuming dilution $1.94 $1.78 9.4%

Weighted average number of shares

Basic 25,824 26,746

Diluted 26,746 27,649

Inc/(Dec) vs

prior year

profit

Profit Margins: margin %

Gross profit 49.9% 50.6% (0.7%)

R&D 4.7% 5.4% (0.7%)

S,G&A 31.6% 30.5% 1.1%

Operating income 13.6% 14.0% (0.4%)

Income before taxes 15.0% 16.1% (1.1%)

Net income 10.1% 10.9% (0.8%)

Revenue Analysis for Fourth Quarter FYE08 and FYE08 YTD

Fourth Quarter Twelve Months Ended

3/29/08 3/31/07 3/29/08 3/31/07

As As % Inc/ As As % Inc/

Reported Reported (Dec) Reported Reported (Dec)

Revenues by Geography

United States $62,727 $50,570 24.0% $232,812 $193,620 20.2%

International $76,012 $66,349 14.6% 283,628 255,987 10.8%

Net Revenues $138,739 $116,919 18.7% $516,440 $449,607 14.9%

Disposable Revenues by Product Family

Donor:

Plasma $40,430 $30,718 31.6% $155,219 $126,971 22.2%

Blood
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... Researchers at the University of Chicago have discovered a ... has obstructive sleep apnea (OSA) or habitual snoring by ... the possibility of developing a relatively simple urine test ... alleviate the need for costly and inconvenient sleep studies ... percent of whom actually have OSA," said lead author ...
(Date:12/6/2009)... become a mainstay of multiple myeloma treatment may ... of patients who have received stem cell transplants ... clinical trial results to be presented by ... Society of Hematology,s (ASH) annual meeting on Sunday, ... Center, Room 243-245, 5:45 pm CT). , ...
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 2b 003-A1 study, known as the 003 trial, ... relapsed and refractory multiple myeloma patients. These data ... at the 51st annual meeting of the American ... in this trial is complete (n=269), and full ...
(Date:12/6/2009)... of the community, in cooperation with the Greater VA Healthcare System ... This year,s attendance is expected to soar to more than 5,000 ... ... (PRWEB) December 6, 2009 -- Volunteer organizations and members ... in West Los Angeles, will once again create a holiday party. ...
(Date:12/5/2009)... Africa, December 5 The first Football,for Hope ... Town opened its doors,today (5 December 2009). FIFA ... Premier Helen Zille, 2010 FIFA World Cup Organising ... Football Association,President Kirsten Nematandani and Executive Mayor of ...
Breaking Medicine News(10 mins):Health News:Urine test for pediatric obstructive sleep apnea possible 2Health News:Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 2Health News:Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha 3
... 11 On the eve of a vote to,expand ... be concerned that spirituality is about to be squeezed ... Speaker Fabian Nunez, California assemblymen are,flocking to the capitol ... 1, a bill,intended to provide universal health care coverage ...
... TORONTO, Dec. 11 /PRNewswire/ - A popular class of ... A new Canadian study released by,the Institute for Clinical ... the risk of heart failure, heart attacks and death., ... ICES scientists looked at,the glitazone class of drugs including ...
... as many as one in five people over age ... the body, some degree of backward leakage occurs across ... (MR). When sufficiently severe, MR causes buildup of blood ... or "shortness of breath"), a serious condition called congestive ...
... Several extraordinary recent achievements place the field of ... the Dec. 10 issue of Optics Express, papers ... nanojets" for biomedical applications and the longest photon ... date. According to Dr. Vasily Astratov from ...
... (Dec. 10, 2007) -- With findings highlighted on a ... Medical College in New York City have shed important ... Epithelial cells line the outside of nearly all organs. ... in developed epithelial cells that selects from a large ...
... Cold Spring Harbor Laboratory (CSHL) scientists recently led ... space radiation on astronauts. The results of their study ... the safety of crew members participating in long distance ... caused by space radiation will be important during extended ...
Other Medicine News:Health News:More evidence suggests diabetes drug may be dangerous 2Health News:More evidence suggests diabetes drug may be dangerous 3Health News:Exercise testing may help predict seriousness of mitral regurgitation 2Health News:IBM reports milestone in silicon nanophotonics 2Health News:Protein-dependent 'switch' regulates intracellular trafficking in epithelial cells 2Health News:Protein-dependent 'switch' regulates intracellular trafficking in epithelial cells 3Health News:Brain stem cells sensitive to space radiation 2Health News:Brain stem cells sensitive to space radiation 3
(Date:12/4/2009)... Suneva Medical, a privately-held aesthetic medical device company, ... President and Chief Financial Officer. In this role, ... administrative functions including finance, accounting, IT, IR, administration and ... Company,s senior management team. ,, "One of my ...
(Date:12/4/2009)... Shore and E. David Crawford presented results for prostate-specific ... end points of biochemical recurrence rate in a Phase ... or monthly leuprolide in prostate cancer patients during the ... received FIRMAGON 240/80 mg/month had a recurrence rate of ...
(Date:12/3/2009)... a subsidiary of Hill-Rom Holdings, Inc. (NYSE: ... Allen Amatech(TM) OEM (Original Equipment Manufacturer) business website ... the Allen Amatech(TM) brand identity and includes an online ... and design specifications for the products. "We hope to ...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Angelica Corporation Raises Bar Again for Increased Patient Safety 48022 1Angelica Corporation Raises Bar Again for Increased Patient Safety 48022 2Univisions Doctora Aliza Launches VidaySalud com 28TM 29 48017 1Univisions Doctora Aliza Launches VidaySalud com 28TM 29 48017 2Ortho Biotech Oncology Research 26 Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer 48014 1Ortho Biotech Oncology Research 26 Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer 48014 2Ortho Biotech Oncology Research 26 Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer 48014 3Ortho Biotech Oncology Research 26 Development Announces Collaboration with National Cancer Institute to Develop Novel Cell Therapies to Treat Cancer 48014 4
... ALISO VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 ... presentation of,Phase III data, including efficacy, ... patients with diabetic peripheral,neuropathic (DPN) pain ... (DM/Q)), an NMDA receptor,antagonist and sigma-1 ...
... Data presented at Movement Disorder Society’s 11th,International ... early,Parkinson’s disease patients is a critical unmet ... – Merck Serono S.A.,(virt-x: SEO) and its ... data, which suggest that safinamide, a new,agent ...
Other Medicine Technology:AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease 2Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease 3Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease 4Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease 5Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease 6Promising Data on Cognitive Effects of Safinamide in Early,Parkinson's Disease 7
... Exp Expandable Tip System A lower cost ... you to perform multi-sample transfers between two different ... a knob, tip spacing can be quickly and ... or 96 well plates. Ergonomic Design for ...
... Tip System A lower cost alternative to ... perform multi-sample transfers between two different vessel configurations. ... tip spacing can be quickly and easily adjusted ... well plates. Ergonomic Design for Unparalleled Comfort ...
... A lower cost alternative to Equalizers, the patented ... between two different vessel configurations. With the push ... be quickly and easily adjusted for test tubes ... Ergonomic Design for Unparalleled Comfort Pick one ...
... Exp Expandable Tip System A lower ... allows you to perform multi-sample transfers between two ... of a knob, tip spacing can be quickly ... tubes) or 96 well plates. Ergonomic Design ...
Medicine Products: